The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For us, halfway through the 2020s, it’s Mounjaro vs Ozempic, the battle of the fat jabs. In the first ever head-to-head ...

The administration might be launching a campaign specifically targeting such products. This would follow Monday's executive ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications . The study was ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

A leading obesity doctor has said a new trial of weight loss drugs Mounjaro and Wegovy may lead advertisers to reconsider their prices.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...